We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $759.18 as of February 3rd. REGN’s trailing and forward P/E were 18.30 and 17.24 respectively according to Yahoo Finance. Pixabay/Public Domain Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34446 ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings.The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expen ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings.The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expen ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosingTARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. T ...

Market Analysis by covering: Abrdn Life Sciences Investors, Roundhill Magnificent Seven ETF, Defiance Large Cap ex-Mag 7 ETF. Read 's Market Analysis on Investing.com ...

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has shown steady revenue growth, with a 3% increase in fourth-quarter sales compared to the previous year, driven by double-digit growth in three key products [2][3] Sales Performance - Global net sales of DUPIXENT increased by 32%, while LIBTAYO sales rose by 13% on a constant-currency basis [3] - In the U.S., EYLEA HD sales surged by 66%, indicating strong momentum in the domestic market [3] Product Highlights - DUPIXENT is described as a core pillar of Regeneron's business, currently used by over 1.4 million patients worldwide, with further growth anticipated [4] - LIBTAYO has shown progress, particularly in adjuvant CSCC and gaining market share in advanced non-small cell lung cancer, becoming the second most prescribed immunotherapy in the first-line setting in the U.S. [4] Future Outlook - The company has a busy regulatory and development agenda, expecting at least four FDA approvals, including three new molecular entities and the EYLEA HD prefilled syringe [5] - Plans include launching 18 additional Phase III studies over the coming years, with an estimated total enrollment of about 35,000 patients, aimed at supporting the next wave of potential blockbuster products [5]

Core Insights - Regeneron Pharmaceuticals, Inc. reported Q4 2025 results with revenue of $3.9 billion, a 3.0% increase year over year, exceeding consensus expectations by approximately 3% [1] - Adjusted EPS for the quarter reached $11.44, which is 7% above street expectations, indicating strong profitability [1] - The company's performance is driven by four blockbuster medicines and a promising late-stage clinical portfolio, with significant label expansions and new solutions for EYLEA HD [1] Financial Performance - Q4 revenue was $3.9 billion, reflecting a 3.0% year-over-year growth [1] - Adjusted EPS for Q4 was $11.44, exceeding expectations by 7% [1] - BofA Securities projected Q4 collaboration revenues from Sanofi at $1.6 billion, a 32% increase year over year, while Bayer collaboration revenues were estimated at $361 million, down 4% year over year [3] Product Developments - EYLEA HD received label expansions, enhancing its commercial potential [1] - Dupixent has new approvals in Japan and Europe, with over 1.4 million active patients globally, making it the most widely used innovative branded antibody medicine [1] - Libtayo secured additional approvals and remains a leading immunotherapy for non-melanoma skin cancers [1] Analyst Ratings and Projections - BofA Securities maintained a Buy rating with a price target of $860, incorporating the impact of R&D estimates and other disclosures [2] - Evercore ISI raised the price target to $875 from $750, reiterating an Outperform rating, emphasizing Dupixent's growth and Eylea HD's competitive prospects [4] - For 2026, BofA estimated U.S. Eylea franchise revenues at $4.43 billion, higher than previous forecasts and consensus [3]

Core Viewpoint - Regeneron (REGN) reported Q4 2025 results that slightly exceeded market consensus, with no major surprises noted in the earnings report [2]. Financial Performance - The company provided expense guidance for 2026, indicating a focus on managing costs while maintaining growth [2]. Product Updates - Regeneron pre-announced Eylea, which is a significant product for the company, although specific details were not disclosed in the report [2].

Raymond James upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to an "Outperform" rating, raising the price target from $820 to $870.The company's Q4 2025 earnings call likely highlighted key financial metrics and strategic plans, supporting a positive future outlook.Despite a slight decrease in stock price to $741.45, Regeneron's market performance remains dynamic, with a significant market capitalization of approximately $76.58 billion.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biote ...